Elena Desillier, MD
Interventional Pain Medicine · Brighton, MANPI 1548365554
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 29.2% of the total. That places this record below the midpoint for interventional pain medicine clinicians in MA, where the typical reported total is $4,278.
Across 142 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$820
- AbbVie$331
- Collegium Pharmaceutical, Inc.$235
- Scilex Pharmaceuticals Inc.$171
- Redhill Biopharma Inc.$165
- Averitas Pharma Inc.$164
- plus $921 from 23 others
What the payments were for
- Food & beverage$2,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $820 |
| AbbVie | 15 | $331 |
| Collegium Pharmaceutical, Inc. | 13 | $235 |
| Scilex Pharmaceuticals Inc. | 7 | $171 |
| Redhill Biopharma Inc. | 12 | $165 |
| Averitas Pharma Inc. | 6 | $164 |
| Abbott | 2 | $129 |
| Biodelivery Sciences International, Inc. | 7 | $101 |
| Lilly USA, LLC | 3 | $70 |
| Electronic Waveform Lab, Inc. | 4 | $60 |
| Vertex | 2 | $57 |
| Valinor Pharma, LLC | 3 | $56 |
| Relievant Medsystems, Inc. | 2 | $41 |
| Pfizer | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Boston Scientific | 1 | $30 |
| Johnson & Johnson | 1 | $29 |
| Bioventus LLC | 1 | $28 |
| GRT US Holding, Inc. | 1 | $26 |
| Si-bone, Inc. | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Stimwave Technologies Incorporated | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$106
How this compares
$2,807 in reported general payments places this provider in the 45th percentile of 22 interventional pain medicine providers in Massachusetts.
See all interventional pain medicine providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 38 | $30,360 |
| OxycontinOxycodone Hcl | 16 | $6,882 |
| Buprenorphine | 28 | $5,333 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 148 | $4,239 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 126 | $3,989 |
| Oxycodone Hcl | 99 | $2,068 |
| Gabapentin | 74 | $976 |
| Pregabalin | 18 | $763 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $727 |
| Tramadol Hcl | 45 | $630 |
| Baclofen | 11 | $245 |
| Morphine Sulfate | 12 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $235 | $30,36038 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $38 | $5,53940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 22 interventional pain medicine providers in Massachusetts.
Other interventional pain medicine in Brighton
- Warren Mackie-JenkinsBoston$65K
- Mark JonesBoston$48K
- Frederic GergesBoston$21K
- David DibenedettoWaltham$17K
- Anil KumarStoneham$8K
- Omar QureshiFitchburg$7K
- Rami RustumMethuen$6K
- Janet PearlFramingham$5K
- Yuri KhibkinHolyoke$5K
- Erica BialBurlington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.